Reading RVPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVPH free→Reading RVPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVPH free→Health CareSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and risk is high. The sector backdrop is a headwind, which may affect RVPH's performance compared to its peers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $0.70. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.21x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
13 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Reviva plans to initiate the RECOVER-2 Phase 3 trial in the first half of 2026, subject to sufficient financing.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$430.
How much price usually moves either way.
On a bad day, this stock has moved -$1,462.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $9,802.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RVPH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the “Company”) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (“Nasdaq”) and the Company had until May 11, 2026, which was the maximum extent of t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
A side-by-side read on sector standing, valuation, and risk versus Health Care (broad).
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RVPH Reviva Pharmaceuticals Holdings Inc | — | — | high |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
UNH UnitedHealth Group | Above typical Show detailsSector percentile: 76 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Stated in 2 of last 2 quarters. The company has reiterated its plan to initiate the RECOVER-2 Phase 3 trial in 2026, with trial activities expected to start in Q2 and patient enrollment in Q3. However, financial constraints may impact the timeline, as indicated by the need for sufficient financing.
“We expect to initiate trial related activities in Q2 2026 and begin patient enrollment in the United States in Q3 2026.”
“Subject to sufficient financing, Reviva plans to initiate the RECOVER-2 Phase 3 trial in the first half of 2026.”
Reviva remains focused on disciplined execution to bring the RECOVER-2 trial toward regulatory approval.
Newly stated in 2026-Q1. The company emphasizes disciplined execution for the RECOVER-2 trial, aiming for regulatory approval. However, financial results show a net loss of $3.2 million in 2026-Q1, indicating financial challenges that may affect execution.
“With plans to initiate the RECOVER-2 registrational trial in mid-2026, we remain focused on disciplined execution and bringing this promising therapy toward regulatory approval.”
Reviva is addressing compliance with Nasdaq's minimum bid price requirement to maintain its listing.
Stated in 2 of last 2 quarters. Reviva is addressing compliance with Nasdaq's minimum bid price requirement, as it was not in compliance in 2026-Q2. The company received an exception from Nasdaq in 2026-Q1 to demonstrate compliance, but financial challenges persist with a net loss of $3.2 million in 2026-Q1.
“The common stock of Reviva was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2).”
“Nasdaq Hearings Panel notified Reviva of an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement.”
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Other Events. The Company is including the below update to its risk factors, for the purpose of supplementing and updating the “Risk Factors” disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026. The below update should be read in conjunction with the “Risk Factors” disclosure appearing in the foregoing report, as further supplemented and updated in the Company’s other fi…
of this Current Report on Form 8-K, on April 15, 2026, the Company issued a letter to shareholders announcing certain business updates, including in connection with the Company’s program for the development of brilaroxazine for the treatment of schizophrenia and regarding the Company’s intellectual property strategy. The Company announced certain efforts centered on extending the long-term value of the brilaroxzine program and preparing for the next phase of development. A component of that s…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…